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Trypanosoma cruzi,  the protozoan parasite which causes Chagas' disease, has a 
complex life cycle that involves both insect and mammalian hosts. The epimas- 
tigote (Epi) l stage of T. cruzi, which multiplies in the gut of the vector, is rapidly 
lysed in human serum by means of alternative complement pathway activation 
(1).  In  contrast,  the  infective metacyclic trypomastigote stage,  the amastigote 
stage, which multiplies intracellularly in the vertebrate host, and the bloodstream 
trypomastigote form are not lysed when incubated in human serum (1, 2). This 
type of adaptation to the mammalian host is commonly observed with protozoan 
parasites, but little is known about the mechanism by which these parasites are 
transformed from activators to nonactivators of the alternative pathway. The 
membrane molecules on the Epi stage of T.  cruzi  that activate the alternative 
complement pathway have not been identified. Similarly, the membrane mole- 
cules on vertebrate forms that prevent alternative complement pathway activa- 
tion are not characterized. Although a  trypsin-sensitive surface protein or gly- 
coprotein apparently blocks alternative complement pathway activation in blood- 
stream  trypomastigotes (2),  the  identity of this  molecule(s)  is  unknown.  By 
studying the interaction of complement proteins with the surface of T. cruzi, we 
hope to elucidate the mechanism by which vertebrate life cycle forms evade lysis 
by the alternative complement pathway. 
Complement component C3  is a  pivotal molecule in complement activation 
and  complement biology. C3  is  cleaved during both  classical  and  alternative 
pathway activation, generating the  fragments C3a  and C3b.  The  larger  C3b 
fragment binds to the activating surface, and in so doing may serve as an opsonic 
molecule for cells bearing C3b receptors. Alternatively, C3b may function with 
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earlier components of the cascade to form the classical or alternative pathway 
C5  convertase (3,  4),  a  necessary step for the generation of C5b and the lytic 
C5b-9 complex. Finally, depending on the nature of the activating surface, C3b 
may be cleaved further to iC3b or C3dg, fragments that can no longer participate 
in C5 convertase formation. Thus, it is apparent that C3 plays a  central role in 
determining the outcome of the interaction between complement and activating 
particles.  In this regard, determination of the molecular site of C3b deposition 
(the C3  acceptor) and the nature of the bond between C3b and the activating 
surface may provide important clues to the fate of particles bearing C3b. 
We therefore sought to identify those surface molecules on the complement- 
activating stage  of T.  cruzi  to  which  C3b  attaches during incubation  in  fresh 
serum.  Using a  recently developed (5)  method for determining the membrane 
acceptor site for C3 deposition, we show here that gp72, a major developmentally 
regulated surface glycoprotein (6-12),  is the preferential acceptor for C3 depo- 
sition on T. cruzi Epi during alternative pathway activation in nonimmune serum. 
In  contrast,  we  find  that  minimal  deposition  of C3  occurs  when  metacyclic 
trypomastigotes (CMT) produced in vitro are incubated in serum, and that gp72 
on CMT is a  poor acceptor for C3.  This is the first study to elucidate the C3 
acceptor molecule on a protozoan parasite. 
Materials and Methods 
Buffers.  The following buffers were used in these experiments: Hanks' balanced salts 
solution  containing 0.15  mM  CaCI2 and  1.0  mM  MgCI~ (HBSS);  lysis buffer  (LB), 
containing 0.05 M Tris, 100 mM NaCI, 2% Nonidet P-40, and 0.5% sodium deoxycholate 
(pH 8.2); low ionic strength (U -- 0.060) Veronai-buffered saline containing 0.1% gelatin, 
5% dextrose, 0.15 mM CaCI~, and 1.0 mM MgCI~; Eagle's minimal essential medium; and 
Dulbecco's phosphate-buffered saline (DPBS), pH 7.2. 
T. cruzi Strains.  The Tulahuen strain (13) and the Miranda 88(M88)  clone (14) of T. 
cruzi were obtained from J.  Dvorak (NIH,  Bethesda,  MD).  Epi  of these isolates  were 
maintained by serial passage in liver-infusion tryptose broth (Oxoid, Basingstoke, Hants, 
Great Britain) containing 10% (vol/vol) fetal calf serum, 0.02 mg/ml heroin, 100 U/ml 
penicillin, and 100 t~g/mi streptomycin (LIT medium) (15). Parasites were I~own at 26 °C 
and passaged every 7-10 d. Epi in the logarithmic growth phase (<2 ×  10' Epi/ml) were 
used in all experiments. 
CMT were produced in  vitro using a  modification of the  method of Sullivan (16). 
Briefly, Epi of the M88 clone were grown in LIT medium and harvested at concentra- 
tions <7 ×  l0 T Epi/ml. The Epi were washed twice in DPBS and resuspended at 7 ×  106 
Epi/ml in Grace's insect medium (Gibco, Grand Island, NY) supplemented with 10% heat- 
inactivated fetal calf serum and 25 mM Hepes, and adjusted to pH 6.6.40-ml volumes of 
o  2  the parasites were then maintained at 28  C in flasks with 75-cm  surface area for 6-8 d, 
at which time 30-55% CMT were observed. 
CMT were separated from Epi using an adaptation of the procedure of Lanham and 
Godfrey (17). The parasite mixture was washed three times in a phosphate-buffered saline 
solution containing 5.4% glucose (ionic strength 0.217 osM, pH 8.0), and passed through 
a DE52 column (Whatman, Inc., Clifton, NJ)  1 cm high, set in the base of a  10-ml glass 
pipette. ~4 ml of the washed parasites, at 10  s parasites/mi were passed through each of 
these columns, and typically 5-20% of input CMT were recovered in a solution containing 
95% CMT. 
Epi and CMT were surface-iodinated with [125I]Na (New England Nuclear, Boston, 
MA)  and  Iodogen (Pierce  Chemical Co.,  Rockford,  IL), using a  modification of the 
method of Howard et al. (18), as previously described (6). After labelling, parasites were 1198  C3  DEPOSITION  ON  T.  CRUZI 
noted to be intact and motile in all instances.  Specific activity was generally  10  7 cpm for 
108 parasites. 
Complement  Source.  Normal  human  serum  (NHS)  serum  was  obtained  from  nine 
healthy adult volunteers, pooled, and frozen in  multiple aliquots at -70°C. Serum was 
obtained from a patient with congenital deficiency of C8 (C8D).  For some experiments, 
C8D  serum  was  absorbed  with  Epi  before  use,  to  remove any  natural  anti-T,  cruzi 
antibody. 4 ml C8D serum was incubated at 0°C for 30 min with 5 ×  108 Tulahuen Epi, 
then the Epi were removed by centrifugation at 2,000 g for 15 min. C8D serum absorbed 
in this fashion lost <15% of starting C3 titer, as measured by hemolytic assay (see below). 
For some experiments, C8D serum was chelated with  10 mM EGTA and 2 mM MgCI2, 
to limit  complement activation to the alternative complement pathway. C8D serum for 
control tubes was heated at 56°C for 30 min (A56 C8D) to block complement activation. 
Antibodies.  Monoclonal antibody WlC 29.26 (IgG2a) was used for some immunopre- 
cipitation experiments. WIC 29.26 recognizes an epitope within the carbohydrate portion 
of gp72 on Epi  of all strains and clones of T.  cruzi (7). WlC  29.26  was purified from 
ascites by absorption and elution on protein A-sepharose. Rabbit antiserum against gp72 
was prepared by immunizing rabbits with purified gp72, as described previously (7). 
Goat IgG anti-human C3 was prepared as previously described (19),  and coupled to 
Sepharose 4B. Antibodies coupled to anti-C3-sepharose recognized determinants on native 
human C3,  and on all  membrane-bound breakdown products of C3  (iC3b and  C3dg) 
generated during complement activation. 
Purification  and Radiolabelling  of C3.  C3  was purified  to homogeneity using minor 
modifications of the method of Hammer et al. (19), as previously described (20). C3 was 
radiolabeled  with  [3H]sodium borohydride (New  England  Nuclear),  by the  process of 
reductive methylation, to sp act 1.17  X 105 dpm/t~g.  The hemolytic titers of purified C3 
and of C3 in serum were measured essentially  as described by Gaither and Frank (21). 
Complement-mediated Lysis Assay.  Lysis of Epi and CMT by NHS was measured. Log- 
phase Epi and CMT, purified as described above, were washed, and suspended in Eagle's 
minimal essential  medium. NHS was added to achieve a final concentration of 1.6-50%. 
The final  parasite concentration was 5 x  106 Epi or CMT/ml.  Mixtures were incubated 
for 60 min at 37 °C. Motile organisms were then counted in a hemacytometer, and results 
were compared to the numbers found for cultures containing NHS that had been heated 
for 60 rain at 56°C to block complement activation. 
125  125  Preparation of C3 Acceptor  from  l-Epi and  I-CMT.  Surface-iodinated parasites were 
washed twice  in  DPBS and suspended at  106 parasites/ml in HBSS.  Parasites were then 
mixed vol/vol with C8D serum or A56 C8D serum, and the mixtures were incubated at 
37°C for 45  rain  with periodic agitation.  Parasites  were washed three  times  in  HBSS 
containing  25  #M  serine  esterase  inhibitor p-nitrophenylguanidino benzoate  (NPGB) 
(Sigma Chemical Co., St. Louis, MO). The parasite pellet was solubilized  either by boiling 
in  1.0% sodium dodecyl sulfate (SDS) at 100°C for 5 min, or by rotation for 16 h at 4°C 
in  LB containing 25 #M  NPGB.  The detergent-insoluble pellet  (10.2  +  6.1%  of total 
counts  in  six  experiments)  was  removed  by  centrifugation  at  12,500  g  for  5  min. 
Supernatant samples  in  1% SDS were diluted  1:25 in NPGB-LB to achieve a  final  SDS 
concentration of 0.04%. 
Supernatant samples  were precleared by rotation for 1 h at room temperature (RT) 
with 0.4 ml of packed Sepharose 4B per milliliter  of supernatant. This resulted in removal 
of 4-7 % of total ~25I counts. Precleared supernatants were then applied to anti-C3 coupled 
to Sepharose at 0.4 ml of packed resin per milliliter,  and rotated at RT for 3 h. Anti-C3- 
sepharose  was  washed  five  times  in  NPGB-LB, or  until  wash  supernatants  contained 
<0.1% of total applied ~25I counts. In preliminary experiments, >89% of C3 in supernatant 
samples bound to anti-C3-sepharose under these conditions. 
Anti-C3-sepharose bearing ~2~I-Epi or -CMT protein was then handled in two separate 
ways. To determine the extent of covalent attachment of ~I-iabeled Epi or CMT protein 
to C3, the anti-C3-sepharose resin bearing C3 and bound ~I  was boiled in SDS sample 
buffer,  and  applied  to  a  7.5-15%  SDS-polyacrylamide gel,  as  described  below.  To 
determine the identity of the C3 acceptor molecule by SDS-polyacrylamide gel electro- JOINER  ET  AL.  1199 
phoresis (SDS-PAGE), it was necessary to cleave the bond between C3 and its acceptor 
molecule.  Oxyester linkages were  cleaved by incubation  of anti-C3-sepharose bearing 
~z~l-Epi or -CMT protein in  1 M  NH2OH in NPGB-LB (pH  10.5) at 37°C for 30 rain. 
The supernatant was dialyzed overnight at 4°C against absolute methanol to precipitate 
released protein.  The  precipitate  was pelleted,  suspended  in  SDS-sample buffer,  and 
analyzed by SDS-PAGE. 
Preparation of  Antiserum Against the C3 Acceptor on Tulahuen Epi.  Antiserum was raised 
against the C3 acceptor molecule on Tulahuen Epi. Unlabelled Epi (5 x  107 Epi/ml) were 
incubated in 50%  C8D or A56 C8D exactly as described above. Washed parasites were 
solubilized in  1% SDS at 100°C for 5 min, diluted  1:25 in NPGB-LB, and rotated with 
anti-C3-sepharose, as outlined. Anti-C3-sepharose was washed five times in DPBS, then 
used for immunization of rabbits. The animals initially received subcutaneous injection of 
a  1:1  mixture of 50%  Sepharose  in  PBS  with complete  Freund's adjuvant; they were 
boosted every 2 wk with a 1:1 mixture in incomplete Freund's adjuvant. The rabbits were 
bled  2  wk after the  last  immunization  (yielding anti-acceptor serum). Control animals 
were immunized with anti-C3-sepharose that had previously been incubated with lysates 
from Epi incubated in A56 C8D serum (A56 anti-acceptor). 
lmmunoprecipitation of Labeled T. cruzi Components.  5  ×  107  125I-Tulahuen Epi were 
solubilized in  1 ml of lysis buffer at 4°C for 16 h. The detergent-insoluble residue was 
removed by centrifugation. After preadsorption with Sepharose 4B at 4°C for 1 h, either 
10 #1 of W 1C 29.26,  10 ttl of anti-C3 acceptor antiserum, or 10 t~l of antiserum against 
gp72 were added per milliliter of supernatant. Controls for immunoprecipitation experi- 
ments included normal rabbit serum and  A56 anti-acceptor serum. The mixtures were 
incubated for 2 h at 4°C, then 0.05 ml of protein A-sepharose was added per milliliter 
of supernatant.  Incubation was continued  for  1 h  at 4°C,  after which the protein  A- 
sepharose was washed five times at RT in LB, and bound 12~I-labeled protein was released 
and prepared for SDS-PAGE by boiling in SDS sample buffer. 
Immunoblotting of Tulahuen Epi.  4 ×  108 Tulahuen Epi were solubilized at 100°C in 
200 ~! 1% SDS containing 25 #M NPGB. The detergent-insoluble residue was removed 
by centrifugation at  12,500 g for 3 min. Protein content of the soluble supernatant was 
determined (22) and 15 #g of protein was applied to each lane of a  10% SDS-polyacryl- 
amide gel. Following electrophoresis, samples were transferred to nitrocellulose (Millipore, 
Beford, MA) as described previously (23).  Nitrocellulose strips were incubated with 2% 
bovine serum albumin, then developed with a  1:200 dilution of either anti-acceptor, A56 
anti-acceptor,  anti-gp72,  or  an  antiserum  raised  against  whole  Tulahuen  Epi,  kindly 
provided by Dr. Vera Bongartz. Finally, nitrocellulose strips were incubated with 2 x  105 
cpm/m1125I-protein A (New England Nuclear), and autoradiography was performed on 
the dried strips. 
SDS-PAGE.  7.5-15%  SDS-polyacrylamide gels were prepared using Acrylade (FMC 
Corp.,  Rockland, ME) mounting, as previously described (7).  Samples were electropho- 
resed at 30 mA/gel, until the tracking dye entered the gradient gel, then at 50 mA/gel 
thereafter. Gels were stained with Coomassie brilliant blue and dried overnight in a dry 
37°C  oven.  Autoradiography  was  performed  with  XAR-5  film  (Eastman  Kodak  Co., 
Rochester, NY) with Lightning Plus Intensifying Screens. Molecular mass markers (Bio- 
Rad  Laboratories, Richmond, CA) were:  myosin (200  kilodaltons [kD]),  /3-galactosidase 
(116.3 kD), phosphorylase B (97.4 kD), bovine serum albumin (66.2 kD), ovalbumin (45 
kD), carbonic anhydrase (31 kD), soybean trypsin inhibitor (21.5 kD), and lysoszyme (14.4 
kD). 
Results 
Consumption  and  Deposition  of C3  by Epi  and  CMT During Incubation  in  Se- 
rum.  In  initial  experiments,  we confirmed  previous observations that  Epi  are 
lysed during incubation in NHS, whereas CMT are resistant to lysis at all serum 
concentrations (Fig.  1). To determine whether this difference was a reflection of 
the extent of complement activation, we compared deposition of C3 on Epi and 1200  C3  DEPOSITION  ON  T.  CRUZI 
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FIGURE  1.  Epi, but not CMT, of M88 are lysed by NHS. Epi and DEAE-purified CMT of 
M88 were incubated at 5 x  106 parasites/ml in increasing concentrations of NHS for 60 rain 
at 37 ° C. Lysis was assessed by visual microscopy of motile organisms. 
CMT during incubation in C8D serum. Five- to six-fold more C3 was bound to 
M88 Epi than to M88 CMT (Fig. 2). 
Binding of 125I-labeled Epi and CMT Protein  to Anti-C3-sepharose.  Binding of 
J25I-labeled  Epi protein to anti-C3-sepharose after serum incubation was quan- 
titated for two T. cruzi isolates (Table I). > 15% of applied 125I-Epi bound to anti- 
C3-sepharose, for both the Tulahuen and M88 strains, after incubation in 50% 
C8D  serum  at  2.5  ×  107  parasites/ml.  The  binding  was  lower  for  parasites 
incubated in 50% C8D at 5 X  107 parasites/ml, possibly reflecting less total C3 
bound per parasite at the higher concentration. Nonspecific binding of 125I-Epi 
constituents to anti-C3-sepharose was significantly lower (1/23-1/25 of total bind- 
ing) for parasites initially incubated at 5.0 ×  107 parasites/ml than at 2.5  ×  10 7 
parasites/ml  (1/12 of total  binding).  Therefore,  a  concentration  of  5  ×  107 
parasites/ml was used for all subsequent experiments. 
In  contrast to  lzSI-labeled Epi  protein,  only 2.64  +  0.57%  of applied  125I- 
labeled CMT protein bound to anti-C3-sepharose for parasites incubated in 50% 
C8D serum. Nonspecific binding for control 125I-CMT incubated in 2~56 C8D 
was 0.59 +  0.31%. These results indicate that the fraction of 125I-CMT proteins 
bearing C3 after serum incubation is only 1/4-1/5 that of 125I-Epi protein. 
C3 Attaches to lz51-labeled Surface Molecules During Antibody-independent  Alter- 
native Complement Pathway Activation.  We next determined the complement and 9 
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FIGURE 2.  CMT bind C3 poorly in comparison to Epi during incubation in serum. Epi and 
7  S  CMT of M88 were incubated  at 5 x 10 parasites/ml  in 10% C8D containing [ H]C3. Molecules 
of C3 specifically  bound per parasite were determined as described in Materials and Methods. 
antibody requirements for C3 deposition.  '"~I-Epi were incubated in C8D serum 
that had been preabsorbed with Epi at 0°C  to remove natural  antibody, or in 
C8D  serum  chelated  with  Mg  +÷ EGTA  to limit complement activation  to the 
alternative  pathway.  In  both  cases,  specific  binding  of  ~25I-Epi protein  was 
equivalent to that in nonabsorbed, nonchelated C8D serum (Table I). This result 
indicates that attachment of C3 to ~25I-surface molecules occurs via the alternative 
complement pathway by an antibody-independent mechanism. 
Covalent Binding of C3 to I~5I-labeled Tulahuen Epi.  Surface-labeled Tulahuen 
Epi contain  six major iodinated  bands on SDS-PAGE,  ranging  from  37 kD to 
118 kD, daltons (37 kD,  57 kD,  72 kD,  89 kD,  100 kD, and  118 kD) (Fig.  3). 
More heavily exposed autoradiograms revealed additional 20- and 210-kD bands. 
The identity of gp72 within native, surface-iodinated Epi is indicated by immu- 
noprecipitation with WIC 29.26, revealing a single band that comigrates with a 
constituent in native Epi. ~2~I-Epi protein that had bound specifically to anti-C3- 
sepharose migrated as a  single broad band of 170-250 kD.  Native 125I-labeled 
Epi proteins were not observed. The increase in molecular weight of native 125I- 
Epi proteins bound to anti-C3-sepharose presumably represents covalent attach- 
ment of the a95I-labeled proteins to C3b (186 kD), iC3b (183 kD), or C3dg (41 
kD). Negligible nonspecific binding of ~2~I-Epi protein to anti-C3-sepharose was 1202  C3  DEPOSITION  ON  T.  CRUZI 
TABLE  I 
Binding of 125I-labeled Epi and CMT Protein to Anti-C3-sepharose  After Serum Incubation 
T. cruzi strain/clone  Parasites per milliliter 
of 50% serum 
Binding to anti-C3-sepharose* 
50% C8D  50% 456 C8D 
Tulahuen Epi 
% 
5 × 107 (4)*  10.24 ± 3.77  0.41 + 0.17 
2.5 × l0  T  (3)  15.69 ___ 3.17  1.34 + 0.58 
5 × 107 (2)  11.13 ±  1.64  §  0.52 --- 0.26 
5 × 107 (2)  9.06 --- 2.41 j  0.30 + 0.25 
M88 Epi  5 X 107 (3)  9.20 __. 0.82  0.40 -.+ 0.03 
2.5 × 107 (2)  15.24 + 2.41  1.26 + 0.43 
M88 CMT  5 x  107 (3)  2.64 + 0.57  0.59 + 0.31 
~ZSl-labeled Epi or CMT of the indicated strain were incubated in either 50% C8D or 50% A56 
C8D serum for 45 rain. The washed parasites were then solubilized in  1% SDS, and following a 
preclearing step on Sepharose 4B, the percentage of applied 12Sl that bound to anti-C3-sepharose 
in NPGB-LB  with 0.04% SDS was determined as described in Materials and Methods. 
* Mean _+ SD. 
* Number of experiments. 
§ 50% absorbed C8D. 
it 50% Mg  +÷ EGTA C8D. 
observed, as indicated by the relative absence of bands from parasites incubated 
in  A56 C8D serum, in which complement activation cannot occur. 
Identification  of C3 Acceptor Molecule.  The covalent linkage between C3 and 
its  acceptor  molecule  on  ~25I-labeled  Epi  obviates  direct  identification  of the 
acceptor  molecule  by  SDS-PAGE.  The  bond  between  C3  and  its  acceptor 
molecule is frequently an ester linkage that can be cleaved by hydroxylamine at 
alkaline  pH  (24-26).  Therefore,  we  treated  anti-C3-sepharose  bearing  lzsI- 
labeled Epi protein with 1 M hydroxylamine at pH  10.5. 125I-Epi protein released 
by hydroxylamine was analyzed by SDS-PAGE. Results from three representative 
experiments,  out  of a  total  of seven  performed,  are  shown  in  Fig.  4.  In each 
case,  five or six  major bands are apparent  for native  Epi,  and there  is  marked 
enrichment  of gp72  when  the  hydroxylamine eluates  from anti-C3-sepharose 
are  compared with  Epi  lysates.  Densitometric scans  (Fig.  5)  showed that  gp72 
comprised 28 +  10%  (mean +SD) of total density in native Epi extracts,  but in 
lanes  containing hydroxylamine-treated eluates  from anti-C3-sepharose,  gp72 
showed 85 +  9%  of the total density. As expected, very little  material was seen 
from hydroxylamine eluates from control samples incubated in A56 C8D serum. 
Selective enrichment of gp72 was observed when Epi were incubated in absorbed 
C8D serum or in Mg  ++ EGTA C8D serum, indicating that gp72 is the preferential 
acceptor for C3 deposited by the alternative pathway in the absence of antibody. 
These  experiments  indicate  that  C3  attaches  preferentially  to  gp72  during 
complement activation by Tulahuen Epi. The absence of significant high molec- 
ular  weight  material  in  experimental  samples  after  hydroxylamine treatment 
indicates  nearly  complete  cleavage  of the  covalent  bond  between  C3  and  its JOINER  ET  AL.  1203 
FIGURE 3.  Autoradiogram  of 7.5-15%  SDS-polyacrylamide gel  showing that  C3b  binds 
covalently to  J251-1abeled Tulahuen  Epi  protein  during  incubation  in  serum,  l~SI-labeled 
Tulahuen Epi at 5 X 107 parasites/ml  were incubated in either 50% C8D or 50% A56 C8D 
for 45 rain at 37 o  C. Detergent lysates of washed parasites were applied to anti-C3-sepharose. 
l~51-labeled Epi protein  bound to anti-C3-sepharose  was analyzed by SDS-PAGE autoradiog- 
raphy. Parasites incubated in 50% C8D are shown in the lane designated A:C3, those incubated 
with A56 C8D in the lane designated A:C3 (A56). Also shown is the detergent lysate from 
intact 125-labeled Epi (Epi Lysate) and the material immunoprecipitated  from detergent lysates 
with monoclonal antibody WIC 29.26, which recognizes gp72. 
acceptor molecule, and is most compatible with the hypothesis of a  C3-acceptor 
ester linkage. 
Selective enrichment  of gp72  in  experimental  samples was not an artifact of 
sample processing.  No such enrichment was seen when large samples of nonspe- 
cifically bound  material,  from either  native  Epi or  Epi  incubated  in  /,56  C8D 
serum, were eluted  from anti-C3-sepharose with hydroxylamine and examined 
by SDS-PAGE autoradiography.  Furthermore, an average of 88.7 +  3.1% of the 
~25I that  bound  to  anti-C3-sepharose  was  released  with  hydroxylamine,  and 
>60%  of released counts were recovered after dialysis against methanol. 
Antiserum Against C3 Acceptor Immunoprecipitates  and Immunoblots gp72.  We 
wished to confirm, by another method, that gp72 was the acceptor molecule for 
C3 deposited on Epi. Antiserum against the C3 acceptor molecule was prepared 
as described  in  Materials  and  Methods,  and  was  used  for immunoprecipitation 
of ~zSI-labeled Tulahuen  Epi surface protein. This antiserum precipitated exclu- 
sively  gp72  from  detergent  lysates  of  125I-labeled  Tulahuen  Epi  (Fig.  6).  In 1204  C3  DEPOSITION  ON  T.  CRUZI 
FIGURE 4.  Autoradiogram  of 7.5-15%  SDS-polyacrylamide  gel  showing  that  C3b  binds 
preferentially to gp72 on 1251-labeled Tulahuen Epi during incubation in serum. Experimental 
conditions were as outlined in the  legend of Fig.  3,  except that  anti-C3-sepharose bearing 
~SI-labeled Epi protein was treated with 1 M NH~OH (pH  10.5) for 30 rain at 37°C to cleave 
ester linkages between C3 and acceptor molecules. Released ~25I-labeled Epi protein was then 
analyzed by 7.5-15 % SDS-PAGE. Three separate experiments are shown comparing detergent 
lysates  of intact  Epi  (Epi  Lysate),  and  of  material  released  from  anti-C3-sepharose  with 
hydroxylamine  after  incubation  in  50%  C8D  (A:C3) or  50%  A56 C8D  [A:C3 (A56)].  Also 
shown for exp.  1 is gp72  immunoprecipitated from detergent lysates with WIC 29.26,  and 
with a rabbit antiserum against gp72 (A:GP72). 
EXP  1 
LYSATE 
A:C3 
EXP  2  EXP  3 
FIGURE 5.  Densitometric scan ofautoradiogram in Fig. 4. JOINER  ET  AL.  1205 
FIGURE 6.  Autoradiogram  of 7.5-15%  SDS-polyacrylamide gel  showing that  antiserum 
against the C3 acceptor immunoprecipitates exclusively gp72. Antiserum was raised agianst 
the C3 acceptor on Tulahuen  Epi as described in Materials and Methods. This antiserum was 
used (A:Acceptor) and compared  with W1C  29.26  for immunoprecipitation of l~I-labeled 
protein from detergent lysates of 125I-labeled  Epi (Epi Lysate). 
contrast,  antiserum  raised  against  intact  Tulahuen  Epi  immunoprecipitated  at 
least  five  additional  bands  from  detergent  lysates  of  125I-Tulahuen  Epi  (not 
shown).  No bands were observed using preimmunization serum from the rabbit 
subsequently used for preparation of anti-C3  acceptor antiserum. Similarly, no 
bands were immunoprecipitated using antiserum raised against Epi proteins that 
had bound nonspecifically to anti-C3-sepharose after incubation of Epi in  A56 
C8D serum. 
We then examined the possibility that membrane molecules other than those 
labelled by the Iodogen procedure also function as C3 acceptors. These molecules 
would not have been detected with the methods employed above. We therefore 1206  C3  DEPOSITION  ON  T.  CRUZ1 
tested the reactivity of anti-acceptor sera for Tulahuen Epi by immunoblotting, 
an assay which does not depend on  surface labelling.  Results were compared 
with control antisera, and with antibodies against gp72,  and against Tulahuen 
Epi. A  doublet of bands (72 and 61  kD) was recognized by both anti-acceptor 
antisera and anti-gp72  antisera (Fig.  7).  It is likely, therefore, that the 61  kD 
component, which may or may not be surface exposed, represents a breakdown 
product of gp72. An additional band of 44 kD was detected in the immunoblot 
with anti-acceptor antisera, but was present with similar intensity when control 
antisera was used. As expected, a variety of additional constituents were detected 
with the polyspecific anti-Epi antisera. These results confirm the findings based 
FIGURE 7.  Autoradiogram of immunoblot showing that antiserum against the C3 acceptor 
(A:Acceptor) specifically recognizes only gp72 on Tulahuen Epi. This antiserum was compared 
with control antiserum (A:Acceptor A56),  antiserum against gp72  (A:GP72), and antiserum 
against whole Tulahuen Epi (A:Epi). JOINER  ET  AL.  1207 
on immunoprecipitation of surface-labeled proteins, and argue that gp72 is the 
only membrane acceptor molecule in Epi. 
Comparison  of C3 Acceptor on Epi and CMT of M88.  gp72 is present on both 
Epi and CMT  forms of T.  cruzi.  The above experiments (Fig.  2  and Table I) 
demonstrate that CMT inefficiently activate complement in comparison to Epi, 
for which gp72 is the acceptor molecule for C3 deposition. We therefore wished 
to identify the acceptor molecule for C3 deposition on CMT. gp72 on M88 Epi 
grown in  LIT  medium gives a  double band containing components of 72  kD 
and 59 kD when immunoprecipitated with either polyclonal anti-gp72 antiserum 
(Fig. 8) or witb WIC 29.26 (not shown). 
gp72 is the principle C3 acceptor molecule on M88 Epi during incubation in 
serum. There is marked enrichment of the gp72  double band in the anti-C3- 
sepharose sample in comparison to Epi lysates (Fig. 8), CMT of M88 demonstrate 
a simpler surface iodination pattern than Epi, with gp72 as the major constituent. 
The molecule in CMT comigrates with the upper band from z~SI-labeled M88 
Epi, and can be immunoprecipitated with WIC 29.26 and anti-gp72 antiserum 
(not shown), suggesting that it is similar if not identical to gp72. However, gp72 
of CMT does not serve as an efficient acceptor molecule for C3 deposition. Not 
only is total C3 deposition on CMT only 1/5 of that on Epi (Fig.  2),  but only a 
faint band at  72,000  dahons is observed in  the C3 acceptor preparation from 
M88 CMT. 
FIGURE 8.  Autoradiogram of 7.5-15% SDS-polyacrylamide gel showing that gp72 on CMT 
of  M88  is  a  poor  acceptor  for  C3  deposition  during  incubation  in  serum.  Experimental 
conditions were as outlined in the legend of Fig.  4, except that Epi and CMT of strain M88 
were used. lmmunoprecipitation of gp72 from M88 Epi using rabbit antisera shows a double 
band with 72- and 59-kD components. 1208  c3  DEPOSITION  ON  T.  CRUZI 
Discussion 
We have shown in this paper that the 72 kD glycoprotein of T. cruzi Epi (gp72) 
is the major acceptor for C3 deposition during alternative pathway activation in 
serum. This was demonstrated by affinity purification, using anti-C3-sepharose, 
of C3 and its accompanying acceptor molecule from detergent lysates of serum- 
incubated  ~-~5I-labeled Epi.  In  addition,  antiserum  raised against  the  affinity- 
purified C3  acceptor molecule immunoprecipitated only gp72  from complete 
lysates of ~25I-labeled Epi and specifically immunoblotted only gp72 from unla- 
belled Epi. Deposition of C3 on gp72 occurs via the alternative pathway, and is 
not dependent upon specific antibody. Deposition of C3 on CMT of T. cruzi is 
inefficient, since only  ~/~ as  much C3  binds  to  CMT  as  to  Epi  during a  l-h 
incubation in serum. Furthermore, gp72  on CMT is not an efficient acceptor 
for C3 deposition, despite being the major surface-labelled constituent. 
Active C3 in serum contains an internal thioester linkage (25,  27).  Cleavage 
of C3 to C3b results in covalent attachment of C3b to acceptor molecules via a 
transesterification reaction (25).  This  reaction can occur at exposed hydroxyl 
groups of mono-, oligo-, and polysaccharides (28,  29).  Transesterification with 
C3b can also occur with proteins. For example, C3b can bind to the carbohydrate- 
free Fd portion of IgG via a  hydroxylamine-sensitive linkage, presumably by a 
transesterification reaction  involving  hydroxyl groups  on  tyrosine,  serine,  or 
threonine (30). Finally, C3 can attach to amino acids or proteins by a hydroxyl- 
amine-resistant linkage, most likely an amide bond (28, 31, 32). Our experiments 
indicate that  C3b  attaches covalently to  Epi  surface glycoprotein by an  ester 
linkage, since the bond can be cleaved with hydroxylamine. 
gp72  is  heavily glycosylated, containing 49%  carbohydrate by weight (33). 
Two classes of carbohydrate chains are present. One class constitutes 15% of the 
total carbohydrate in gp72 and contains mostly mannose, with smaller amounts 
of galactose  and  glucosamine.  The  other  class  constitutes  85%  of the  total 
carbohydrate, and contains a  large amount of phosphate, as well as galactose, 
mannose, fucose, xylose, ribose, and glucosamine. WIC 29.26 binds to an epitope 
contained within this pentose- and phosphate-rich fraction. Sialic acid, a molecule 
that,  in  some  systems,  abrogates  alternative  pathway activation  (34),  is  not 
present. Thus, the carbohydrate moiety of gp72 may serve as the acceptor for 
C3 deposition on Epi. Although our experiments do not allow us to distinguish 
whether C3 forms covalent ester bonds predominantly with the carbohydrate or 
the protein portion of gp72, they do indicate that hydroxylamine-resistant  amide 
bonds between C3b and gp72 are not formed. 
Of interest, Venkatesh et ah (35) have recently published evidence for spon- 
taneous time-, temperature-, and pH-dependent cleavage of the ester linkage 
between C3 and acceptor molecules. This spontaneous release can be prevented 
by SDS. In our early experiments, we alternatively solubilized serum-incubated 
Epi in NPGB-LB at 4°C for 16 h, or by boiling in  1% SDS for 5 min. For SDS- 
solubilized  parasites,  the  results  of SDS-PAGE  suggested  complete  covalent 
attachment of 1~SI-gp72 to C3. For Epi solubilized in NPGB-LB only, SDS-PAGE 
of 'zSI-labeled  Epi  protein  bound  to anti-C3-sepharose  revealed a  prominent 
gp72 band as well as a  band at  170-250  kD. These results suggest that sponta- 
neous cleavage of the  ester  linkage between  C3b  and  gp72  occurred in  the JOINER ET  AL.  1209 
absence of SDS, and prompted us to use SDS solubilization of serum-incubated 
parasites for all subsequent experiments. 
gp72 is present on the surface of Epi from all strains and clones of T. cruzi (7). 
Vaccination of mice with purified gp72 decreased the severity of infection caused 
by challenge with CMT (36), raising the possibility that this antigen may be of 
value as an immunogen. Furthermore, WIC 29.26 inhibits transformation of Epi 
into  trypomastigotes in  vitro  (37),  suggesting  that  gp72  may  be  a  receptor 
involved in the control of differentiation. Our finding that gp72  is the prefer- 
ential acceptor for C3 on Epi, yet fails to bind C3 efficiently on CMT suggests 
that membrane molecules other than gp72 may be important in the regulation 
of complement activation. In particular, other major surface molecules (38-41) 
may be important in complement activation by T. cruzi Epi, possibly by influenc- 
ing the interaction of regulatory proteins H  and I with bound C3 (34, 42). We 
are currently measuring the  ability  of purified  gp72  to  directly activate  the 
complement cascade, and are evaluating the role of other membrane components 
as control elements in complement activation. 
This  is the first study to elucidate the role of the acceptor molecule in  C3 
deposition on the surface of a protozoan parasite. The approach we have used is 
widely applicable to the study of complement-parasite interactions. Evaluating 
the surface molecules that serve as activators, acceptors or regulators for the 
biologically critical C3b moiety provides a means for understanding how parasites 
at  different developmental stages  may evade destruction by  the  complement 
system. 
Summary 
We  examined the  interaction  of complement component C3  with  surface 
molecules on Trypanosoma cruzi. Five- to six-fold more C3 was bound to epimas- 
tigotes (Epi) than to metacyclic trypomastigotes (CMT) of strain M88.  Epi and 
CMT were surface iodinated, then incubated in C8-deficient serum, and deter- 
gent iysates were applied to anti-C3 antibody that had been coupled to Sepharose. 
We  found  that  9.20-10.24%  of applied  t~SI-Epi protein  bound  to  anti-C3- 
sepharose, compared to  2.64%  binding of 125I-CMT protein.  Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis showed that C3 was attached to 12~I- 
Epi protein by a  covalent bond.  Samples eluted from anti-C3-sepharose  with 
hydroxylamine revealed  a  single,  major,  72  kD  band,  suggesting  that  C3b 
attaches almost exclusively to the 72 kD glycoprotein of Epi by a hydroxylamine- 
susceptible ester bond. An antiserum was prepared from lysates of serum-treated 
Epi  that  had  been affinity-purified on anti-C3-sepharose.  This antiserum im- 
munoprecipitated a single 72 kD component (gp72) from surface-iodinated Epi, 
and specifically recognized only gp72 from Epi in immunoblots. In contrast to 
the results with Epi, gp72 on CMT was not found to be an efficient acceptor 
molecule for C3 deposition. The results are the first to evaluate the acceptor site 
for C3 deposition on a parasite, and they show that gp72 on Epi, but not gp72 
on CMT, serves as the preferential acceptor for C3 during antibody-independent 
alternative complement pathway activation. 
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